Journal of Shanghai Jiao Tong University (Medical Science) >
Multiple myeloma with cardiac amyloidosis and secondary adrenal cortical dysfunction: a case report
Received date: 2023-07-14
Accepted date: 2024-02-06
Online published: 2024-04-28
Multiple myeloma is a malignant proliferative disease of plasma cells, and some patients may develop systemic amyloidosis. Cardiac amyloidosis is a common cause of death in these patients. Secondary adrenal insufficiency is caused by dysfunction of the hypothalamus and/or the pituitary gland, and multiple myeloma cases combined with secondary adrenal cortical dysfunction have been rarely reported in China. The patient, 55-year-old, male, was admitted to the Emergency Department of Shenzhen Luohu People's Hospital on June 5, 2018 due to "repeated chest tightness and fatigue for 7 months, and fainting for 1 hour". Later, he was transferred to Department of Hematology and was diagnosed as having multiple myeloma (λ light chain type) with systemic amyloidosis through bone marrow puncture and other examinations. The first course regimen of chemotherapy was bortezomib, cyclophosphamide, and dexamethasone. After the course, the patient was infected with a mixture of bacteria and fungi in the lung and had improvement after treatment. Then the regimen was adjusted to bortezomib and dexamethasone from the second course. After the fourth course, the patient achieved complete remission of multiple myeloma. After the fifth course, the patient experienced severe pulmonary-mixed infection again, which was improved after treatment. Thereafter, the patient presented with refractory hypotension, and decreased levels of cortisol and adrenocorticotropic hormone (ACTH), which was diagnosed as secondary adrenal cortical dysfunction. Hydrocortisone replacement therapy was administered. After 9 courses of chemotherapy, the patient received maintenance treatment with ixazomib. Multiple myeloma was evaluated as a stringent complete response. Cardiac amyloidosis was evaluated as a very good partial response, and secondary adrenal cortical dysfunction was treated with hydrocortisone maintenance therapy and with the cortisol level in the normal range.
ZHOU Lingyun , CHEN Haifei . Multiple myeloma with cardiac amyloidosis and secondary adrenal cortical dysfunction: a case report[J]. Journal of Shanghai Jiao Tong University (Medical Science), 2024 , 44(4) : 537 -542 . DOI: 10.3969/j.issn.1674-8115.2024.04.016
1 | 中国医师协会血液科医师分会, 中华医学会血液学分会. 中国多发性骨髓瘤诊治指南(2022年修订)[J]. 中华内科杂志, 2022, 61(5): 480-487. |
1 | Chinese Hematology Association, Chinese Society of Hematology. Guidelines for the diagnosis and management of multiple myeloma in China (2022 revision)[J]. Chinese Journal of Internal Medicine, 2022, 61(5): 480-487. |
2 | DINNER S, WITTELES W, WITTELES R, et al. The prognostic value of diagnosing concurrent multiple myeloma in immunoglobulin light chain amyloidosis[J]. Br J Haematol, 2013, 161(3): 367-372. |
3 | BHUTANI D, LENG S Y, LENTZSCH S. Fibril-directed therapies in systemic light chain AL amyloidosis[J]. Clin Lymphoma Myeloma Leuk, 2019, 19(9): 555-559. |
4 | BAL S, LANDAU H. AL amyloidosis: untangling new therapies[J]. Hematology Am Soc Hematol Educ Program, 2021, 2021(1): 682-688. |
5 | FALK R H, ALEXANDER K M, LIAO R, et al. AL (light-chain) cardiac amyloidosis: a review of diagnosis and therapy[J]. J Am Coll Cardiol, 2016, 68(12): 1323-1341. |
6 | WECHALEKAR A D, GILLMORE J D, HAWKINS P N. Systemic amyloidosis[J]. Lancet, 2016, 387(10038): 2641-2654. |
7 | DUMAS B, YAMEEN H, SAROSIEK S, et al. Presence of t(11;14) in AL amyloidosis as a marker of response when treated with a bortezomib-based regimen[J]. Amyloid, 2020, 27(4): 244-249. |
8 | SALINARO F, MEIER-EWERT H K, MILLER E J, et al. Longitudinal systolic strain, cardiac function improvement, and survival following treatment of light-chain (AL) cardiac amyloidosis[J]. Eur Heart J Cardiovasc Imaging, 2017, 18(9): 1057-1064. |
9 | MACEDO A V S, SCHWARTZMANN P V, DE GUSM?O B M, et al. Advances in the treatment of cardiac amyloidosis[J]. Curr Treat Options Oncol, 2020, 21(5): 36. |
10 | GERTZ M A. Immunoglobulin light chain amyloidosis: 2022 update on diagnosis, prognosis, and treatment[J]. Am J Hematol, 2022, 97(6): 818-829. |
11 | 中国系统性轻链型淀粉样变性协作组, 国家肾脏疾病临床医学研究中心, 国家血液系统疾病临床医学研究中心. 系统性轻链型淀粉样变性诊断和治疗指南(2021年修订)[J]. 中华医学杂志, 2021, 101(22): 1646-1656. |
11 | Chinese Collaborative Group on Systemic Light Chain Amyloidosis, National Clinical Medical Research Center for Kidney Diseases, National Clinical Medical Research Center for Hematology Diseases. Diagnosis and treatment guidelines for systemic light chain amyloidosis (revised in 2021)[J]. Chinese Medical Journal, 2021, 101(22): 1646-1656. |
12 | HAHNER S, ROSS R J, ARLT W, et al. Adrenal insufficiency[J]. Nat Rev Dis Primers, 2021, 7(1): 19. |
13 | LORIAUX D L, FLESERIU M. Relative adrenal insufficiency[J]. Curr Opin Endocrinol Diabetes Obes, 2009, 16(5): 392-400. |
/
〈 |
|
〉 |